Companies / BOC Sciences / Vedolizumab
BOC Sciences

Vedolizumab | BOC Sciences

Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals for the treatment of ulcerative colitis and Crohn's disease under the trade name Entyvio. Vedolizumab binds to integrin _4_7 (LPAM-1) and blocks _4_7, displaying anti-inflammatory activity.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.